Simpson Thacher Represents C. R. Bard in Acquisition of LifeStent® Business from Edwards Lifesciences
01.14.08
This is only gets display when printing
Simpson Thacher represented C. R. Bard, Inc. in connection with the acquisition by Bard's Peripheral Vascular division of the assets of the LifeStent® product family from Edwards Lifesciences Corporation. Bard and Edwards entered into an asset purchase agreement on December 6, 2007 and closed the acquisition on January 11, 2008.
The Simpson Thacher team involved in this deal includes: Katie Sudol, Kevin Lehpamer, Nick Rontiris and Luc Jansen (M&A); Lori Lesser and Ivan Rothman (IP); Aaron Cohen (Tax); Alvin Brown, Beth Understahl and Joseph Tobin (ECB); Adeeb Fadil (Environmental); and Joe Tringali, David Vann, Michael Naughton, Kimberly Hamm, William Kearney and Jonathan Parker (Antitrust). Invaluable assistance was also provided by Paul Curnin, Caroline Gottschalk, Tom Wuchenich and Doug Bacon.